Characterisation of invasive meningococcal isolates from Italian children and adolescents

Clinical Microbiology and Infection

Volumn 13, Issue 1, 2007, Pages 100-103

  Mastrantonio, P ^a   Sofia, T ^a   Neri, A ^a   Fazio, C ^a   Stefanelli, P ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Adolescents; Children; Group C meningococci; Italy; Meningitis; Neisseria meningitidis

Indexed keywords

CEFTRIAXONE; PENICILLIN G; RIFAMPICIN; SULFADIAZINE;

ADOLESCENT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; CHILD; CHILDHOOD DISEASE; CLUSTER ANALYSIS; CONTROLLED STUDY; HUMAN; INFECTION RISK; ITALY; MAJOR CLINICAL STUDY; MENINGOCOCCOSIS; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA MENINGITIDIS; NONHUMAN; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; TIME SERIES ANALYSIS;

NEISSERIA MENINGITIDIS;

EID: 33845306517     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2006.01570.x     Document Type: Article

References (12)

1. Centers for Disease Control and Prevention. Control and prevention of meningococcal disease and control and prevention of serogroup C meningococcal disease. MMWR 1997; 46: 1-21.
2. Miller E, Salisbury DM, Ramsay ME. Planning, registration and implementation of an immunisation campaign against meningococcal group C disease in the UK: A success story. Vaccine 2001; 20: S58-S67.
3. McGuinness BT, Lambden R, Heckels JE. Class 1 outer membrane protein of Neisseria meningitidis: Epitope analysis of the antigenic diversity between strains, implications for subtyping definition and molecular epidemiology. Mol Microbiol 1993; 7: 505-514.
4. Jodar L, Feavers IM, Salisbury D, Granoff DM. Development of vaccines against meningococcal disease. Lancet 2002; 359: 1499-1508.
5. Feavers IM, Fox AJ, Gray S, Jones DM, Maiden MC. Antigenic diversity of meningococcal outer membrane protein PorA has implications for epidemiological analysis and vaccine design. Clin Diagn Lab Immunol 1996; 3: 444-450.
6. Holst J, Aaberge IS, Oster P et al. A 'tailor made'vaccine trialled as part of public health response to group B meningococcal disease epidemic in New Zealand. Eurosurveill Wkly 2003; 7: 5. http://www.eurosurveillance.org/ew/030724.asp
7. Saez Nieto J, Fontanals AD, Garcia de Jalon J et al. Isolation of Neisseria meningitidis with increase of penicillin minimal inhibitory concentrations. Epidemiol Infect 1987; 99: 463-469.
8. Abdillahi H, Poolman JT. Neisseria meningitidis group B serosubtyping using monoclonal antibodies in whole-cell ELISA. Microb Pathog 1988; 4: 27-32.
9. Clinical and Laboratory Standard Institute. Performance standards for antimicrobial susceptibility testing, 16th informational supplement. M100-S16. Wayne, PA: CLSI, 2006.
10. Maiden MCJ, Bygraves JA, Feil E et al. Multilocus sequence typing: A portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci USA 1998; 95: 3140-3145.
11. Stefanelli P, Fazio C, La Rosa G, Marianelli C, Muscillo M, Mastrantonio P. Rifampicin-resistant meningococci causing invasive disease: Detection of point mutations in the rpoB gene and molecular characterization of the strains. J Antimicrob Chemother 2001; 47: 219-222.
12. Findlow J, Lowe A, Deane S et al. Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vescicle vaccine in toddlers and school children. Vaccine 2005; 23: 2623-2627.